The effect of a multispecies probiotic on the composition of the faecal microbiota and bowel habits in chronic obstructive pulmonary disease patients treated with antibiotics

Short-term antibiotic treatment profoundly affects the intestinal microbiota, which may lead to sustained changes in microbiota composition. Probiotics may restore such a disturbance. The objective of the present study was to investigate the effect of a multispecies probiotic on the faecal microbiota during and after antibiotic intake in patients with a history of frequent antibiotic use. In this randomised, placebo-controlled, double-blind study, thirty chronic obstructive pulmonary disease (COPD) patients treated with antibiotics for a respiratory tract infection received 5 g of a multispecies probiotic or placebo twice daily for 2 weeks. Faecal samples were collected at 0, 7, 14 and 63 d. Changes in the composition of the dominant faecal microbiota were determined by PCR-denaturing gradient gel electrophoresis (DGGE). Changes in bacterial subgroups were determined by quantitative PCR and culture. Bowel movements were scored daily according to the Bristol stool form scale. During and after antibiotic treatment, DGGE-based similarity indices (SI) were high ( >/= 84 %) and band richness was relatively low, both remaining stable over time. No difference in SI was observed between patients with and without diarrhoea-like bowel movements. The multispecies probiotic had a modest effect on the bacterial subgroups. Nevertheless, it affected neither the composition of the dominant faecal microbiota nor the occurrence of diarrhoea-like bowel movements. The dominant faecal microbiota was not affected by antibiotics in this COPD population, suggesting an existing imbalance of the microbiota, which may also have contributed to the lack of effect by probiotic intak

Preparação e caracterização de um biocompósito obtido pela mistura de hidreto de titânio com nitrato de cálcio para implantes dentários

RESUMO Neste trabalho foram realizados estudos sobre a fabricação de um biocompósito à base de titânio para implantes dentários a partir da mistura de pó de hidreto de titânio (92%) com nitrato de cálcio (8% em volume). O pó de hidreto de titânio foi adicionado na solução aquosa de nitrato de cálcio, dissolvido por agitação mecânica, e em seguida os precursores foram misturados e dispersados/homogeneizados por ultrassom. Posteriormente, a mistura foi secada em evaporador rotativo, compactada com 600 MPa à temperatura ambiente, desmoldada e sinterizada em alto vácuo a 1200 oC durante 2 horas. Foi analisada a microestrutrura e fases formadas, as propriedades mecânicas, a rugosidade da superfície, a porosidade aberta, a molhabilidade da superfície e a citotoxicidade do biocompósito. As fases identificadas após a sinterização foram α-Ti e CaTiO3. O limite de resistência em compressão, o módulo de Young (E) e o ângulo de contato do biocompósito diminuíram significativamente com relação ao hidreto de titânio puro sinterizado nas mesmas condições. O limite médio de resistência em compressão do hidreto de titânio foi de 1794,67 MPa e do biocompósito foi de 481,36 MPa. O módulo de Young e o ângulo de contato do hidreto de titânio e do biocompósito foram de aproximadamente 112 GPa e 94 graus, e de 75 GPa e 83 graus, respectivamente. A rugosidade de superfície foi da mesma ordem de grandeza entre os materiais e ficou aproximadamente entre 1,4 e 1,5 µm (Ra) e 1,4 e 1,9 µm (Ra e Sa), medidas com rugosímetro de contato e com microscópio confocal a laser, respectivamente. A porosidade aberta do biocompósito sinterizado foi de aproximadamente três vezes maior do que aquela do hidreto de titânio sinterizado. Nos ensaios de citotoxicidade a porcentagem de células viáveis do biocompósito foi superior àquela do controle negativo e àquela do hidreto de titânio sinterizado

Changes in levels of catalase and glutathione in erythrocytes of patients with stable asthma, treated with beclomethasone dipropionate

Dept. of Pulmonology, University Hospital Maastricht, The Netherlands. In asthmatic patients, antioxidant defence is decreased. Although inhaled corticosteroids decrease asthmatic inflammation and modulate reactive oxygen species (ROS) generation, little is known of their effect on cellular antioxidant levels. The aim of this study was to evaluate the effect of inhaled beclomethasone dipropionate (BDP; 1,000 microg x day(-1)) on erythrocyte antioxidant levels in stable asthmatic patients. Forty patients with stable, mild asthma were treated in a double-blind, placebo-controlled, parallel-group study with BDP 250 microg, two puffs b.i.d. for 6 weeks. At entry and every 2 weeks during treatment, erythrocyte antioxidant levels, haematological parameters, pulmonary function tests and asthma symptoms were determined. The results show that during treatment with BDP, erythrocyte catalase levels increased (at entry (mean +/-SEM) 41+/-4, after 6 weeks 54+/-4 micromol H2O2 x min(-1) x g haemoglobin (Hb)(-1), p = 0.05 in comparison with placebo). Erythrocyte total glutathione levels significantly decreased after 6 weeks treatment with BDP (from 7.0+/-0.4 to 6.6+/-0.3 micromol x g Hb(-1) (p = 0.04)). In the BDP-treated patients, blood eosinophil counts were higher in patients who responded with an increase in erythrocyte catalase levels during BDP treatment, as compared to those not responding ((mean +/-SEM) 340+/-39 and 153+/-52x10(6) cells x L(-1), respectively, p = 0.05). The present study shows that treatment with inhaled bedomethasone dipropionate results in changes in antioxidant levels in erythrocytes of patients with stable, mild asthma. Publication Types: Clinical Trial Randomized Controlled Tria

Risk factors for complications in cochlear implant surgery

Item does not contain fulltex